Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck

Melanoma Research

Volumn 25, Issue 6, 2015, Pages 503-509

  Thierauf, Julia ^a   Veit, Johannes A ^a   Affolter, Annette ^c   Bergmann, Christoph ^b   Grünow, Jennifer ^c   Laban, Simon ^a   Lennerz, Jochen K ^a,e   Grünmüller, Lisa ^a   Mauch, Cornelia ^f   Plinkert, Peter K ^c   Hess, Jochen ^c,d   Hoffmann, Thomas K ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Head and neck cancer; Immunohistochemistry; Mucosal melanoma; PD 1; PD L1

Indexed keywords

BIOLOGICAL MARKER; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CUTANEOUS MELANOMA; CYTOTOXIC T LYMPHOCYTE; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUCOSAL MELANOMA; NECK; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; BIOSYNTHESIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MELANOMA; MIDDLE AGED; MORTALITY; MUCOSA; PATHOLOGY; PROGNOSIS;

AGED; ANTIGENS, CD274; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; PROGNOSIS;

EID: 84946488591     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000197     Document Type: Article

References (35)

1. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012; 5:739-753.
2. Prasad ML, Jungbluth AA, Patel SG, Iversen K, Hoshaw-Woodard S, Busam KJ. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck. Head Neck 2004; 26:1053-1057.
3. Holmst rom M, Lund VJ. Malignant melanomas of the nasal cavity after occupational exposure to formaldehyde. Br J Ind Med 1991; 48:9-11.
4. Dahlgren L, Schedvins K, Kanter-Lewensohn L, Dalianis T, Ragnarsson-Olding BK. Human papilloma virus (HPV) is rarely detected in malignant melanomas of sun sheltered mucosal membranes. Acta Oncol 2005; 44:694-699.
5. Lundberg R, Brytting M, Dahlgren L, Kanter-Lewensohn L, Schloss L, Dalianis T, Ragnarsson-Olding B. Human herpes virus DNA is rarely detected in non-UV light-Associated primary malignant melanomas of mucous membranes. Anticancer Res 2006; 26 (5B):3627-3631.
6. Hodi FS,Friedlander P,Corless CL,Heinrich MC,Mac Rae S,Kruse A,et al. Major response to imatinib mesylate in KIT-mutated melanoma J Clin Oncol 2008 26 2046-2051.
7. Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC. Sunitinib therapy for melanoma patients with KITmutations. Clin Cancer Res 2012; 18:1457-1463.
8. L ourenço SV, Fernandes JD, Hsieh R, Coutinho-Camillo CM, Bologna S, Sangueza M, Nico MM. Head and neck mucosal melanoma: a review. Am J Dermatopathol 2014; 36:578-587.
9. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
10. Chang W, Lee SJ, Park S, Choi MK, Hong JY, Kim YS, et al. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma. Melanoma Res 2013; 23:147-151.
11. Krengli M, Jereczek-Fossa BA, Kaanders JH, Masini L, Beldí D, Orecchia R. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit Rev Oncol Hematol 2 008; 65:121-128.
12. Liao JJ, Parvathaneni U, Laramore GE, Thompson JA, Bhatia S, Futran ND, et al. Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. Head Neck 2014; 36:1162-1167.
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
14. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 20 15; 372:320-330.
15. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-567.
16. Menzies AM, Long GV. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013; 5:278-285.
17. Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol 2014; 25:2433-2442.
18. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:13 4-144.
19. Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012; 18:153-159.
20. van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J, Vergote I. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. Europea n Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol 1997; 50:801-804.
21. Bigelow E, Bever KM, Xu H, Yager A, Wu A, Taube J, et al. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp 2013; 71:2-6.
22. Kim DK, Kim DW, Kim SW, Kim DY, Lee CH, Rhee CS. Ki67 antigen as a predictive factor for prognosis of sinonasal mucosal melanoma. Clin Exp Otorhinolaryngol 2008; 1:206-210.
23. Cheng YF, Lai CC, Ho CY, Shu CH, Lin CZ. Toward a better understanding of sinonasal mucosal melanoma: clinical review of 23 cases. J Chin Med Assoc 2007; 70:24-29.
24. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-5074.
25. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlati on with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014; 23:2965-2970.
26. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed dea th ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94:107-116.
27. Jilaveanu LB,Shuch B,Zito CR,Parisi F,Barr M,Kluger Y,et al. PD-L1 expression in clear cel l renal cell carcinoma: an analysis of nephrectomy and sites of metastases J Cancer 2014 5 166-172.
28. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (a nti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-562.
29. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49:2233-2242.
30. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS,Wang H, et al. PD-L1 ex pression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1:54-63.
31. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37.
32. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-Associated head and neck cancer. Cancer Res 2013; 73:128-138.
33. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza D, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumabrefractor y or-naive melanoma. J Clin Oncol [Internet] 2013; 31:4311-4318.
34. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116:1757-1766.
35. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-264.